Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment

Abstract

Data suggest that atypical antipsychotics may be useful in the treatment of obsessive-compulsive disorder (OCD). We report the case of a patient diagnosed of serious OCD resistant to various antidepressant and antipsychotic treatments (including clozapine). The patient had clinically significant improvement (measured by decrease in the score of the YaleBrown Obsessive Compulsive (Y-BOCS) and the Clinical Global Impression (CGI) scales) in the four weeks alter switching from clozapine to ziprasidone, improvement that was subsequently maintained. The pharmacodynamic characteristics of ziprasidone could make this drug more effective than other antipsychotics as coadjuvant treatment in OCD.